Xolair denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Xolair: Step-Therapy Requirement

UHC's coverage policy for Xolair (omalizumab) typically requires that patients try and fail one or more lower-cost therapies — often including inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, or other agents depending on the indication — before approving a biologic. This "fail-first" protocol is called step therapy. The denial does not mean Xolair is wrong for you; it means UHC wants documented evidence that earlier steps were tried.

## Why This Is Appealable — Including Step-Therapy Exceptions

Federal law and many state laws provide explicit step-therapy override rights. Under step-therapy exception standards (codified in some states and reflected in ACA non-discrimination provisions), you can request an exception without completing the step-therapy protocol if: (a) the required drugs are contraindicated or clinically inappropriate for you, (b) you already tried and failed the required drugs, or (c) your condition is severe enough that a delay would cause serious harm. If any of these apply, document them thoroughly and request a step-therapy exception alongside your appeal.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the timeframe on your denial notice. If medically urgent, request expedited review (72-hour decision requirement).
• External review: If internal appeal fails, an Independent Review Organization can review the step-therapy determination. The external review window is generally four months from final internal denial.

## Documentation to Collect

1. Step-therapy protocol from UHC — download UHC's current Xolair medical policy and list every required step exactly as stated. 2. Prior-treatment history — for each required step drug, document: the medication name, start date, end date, dose used (from your pharmacy records), and the reason for discontinuation or failure (lack of efficacy, adverse reaction, intolerance). 3. Clinical records — office notes, specialist records, and any objective measures of disease control during prior therapy trials. 4. Contraindication or intolerance documentation — if a required step drug is medically inappropriate for you, your prescriber should document the specific clinical reason. 5. Medical necessity letter — your prescriber should address each step in UHC's protocol, confirm what was tried and failed (with dates), and explain why Xolair is the appropriate next step per the relevant specialty guideline (e.g., GINA, AAAAI, or applicable guideline organization).

## Criteria-Mapping Structure

Create a row for each step UHC requires. For each row: name the required drug, state whether you tried it (yes/no), provide the date range and outcome if tried, and provide the clinical reason if not tried. This structure directly answers UHC's criteria and leaves no gaps for a reviewer to exploit.

## Practical Note

If you have prior insurance records showing you completed these steps under a previous plan, include those records. UHC is generally required to credit step-therapy completed under another plan within a reasonable lookback period.